Photo: ARTUR PLAWGO/SCIENCE PHOTO LIBRARY/Getty
A growing body of evidence suggests that the people with greater diversity in their microbiome鈥攖he composition of microorganisms that live on and inside the body鈥攔espond better to cancer treatments called immune checkpoint inhibitors. The results of these studies could be beneficial for people with melanoma, says Jeffrey S. Weber, MD, PhD, deputy director of 黑料福利社 Langone Health鈥檚 Perlmutter Cancer Center.
鈥淭he major drawbacks to the use of checkpoint inhibitors in melanoma and other cancers is, frankly, not everybody responds,鈥 Dr. Weber, also the Laura and Isaac Perlmutter Professor of Oncology in the at 黑料福利社 Grossman School of Medicine, tells Medscape. 鈥淢ore than half the patients of those with metastatic melanoma will be refractory to the treatment with the immune checkpoint inhibitors, i.e., there鈥檚 a lot of room for improvement.鈥
Watch more on (free registration required).
